(Q36762423)

16 August 2017

1 reference

title

The risks and the benefits of mesalazine as a treatment for ulcerative colitis (English)

1 reference

16 August 2017

Alan C Moss

1

1 reference

16 August 2017

Mark A Peppercorn

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Drug Safety

16 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

99-107

1 reference

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

An oral preparation to release drugs in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Mesalamine-associated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Descriptive studies: what they can and cannot do.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Causal or casual? The role of causality assessment in pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Interstitial nephritis from mesalazine: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Mesalazine-associated interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Primary chronic interstitial nephritis in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Comparative Nephrotoxicity of Aspirin and Phenacetin Derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

5-Aminosalicylates and effects on renal function in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Colorectal cancer prevention in ulcerative colitis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.99

21 January 2018

Identifiers

DOI

10.1517/14740338.6.2.99

1 reference

16 August 2017

1 reference